prodchem
Sep 9, 2026
The US chemical industry faces an important regulatory deadline as EPA's authority to collect fees under the Toxic Substances Control Act approaches its September 30, 2026 expiration. Congress is considering whether to renew the fee authority separately or connect reauthorization with broader changes to the nation's chemicals framework.
For pharmaceutical ingredient manufacturers, the debate has implications beyond regulatory fees. Changes to chemical review processes, reporting expectations and EPA's ability to administer TSCA could affect how companies evaluate substances used in manufacturing, maintain compliance records and manage new chemical introductions.
TSCA provides EPA with a framework for regulating industrial chemicals in the United States. Its fee program helps fund part of the agency's implementation costs, including activities connected with chemical review and risk evaluation. Industry groups have described the fees as supporting roughly 25% of the program's costs.
The current fee authority expires on September 30, 2026. Congressional action therefore has the potential to influence both the immediate funding structure and the wider direction of TSCA implementation.
For chemical manufacturers, the timing creates a regulatory planning issue. Companies that introduce, import or manufacture substances subject to TSCA may need to track congressional developments alongside their existing compliance obligations.
Pharmaceutical ingredient manufacturing involves a broad network of starting materials, intermediates, solvents, processing chemicals and specialized substances. Some materials may fall under different regulatory frameworks depending on their use, production status and specific circumstances.
TSCA considerations can become particularly relevant when manufacturers introduce chemicals that require EPA review or when companies import chemical substances into the United States. EPA currently maintains fee requirements for several TSCA activities, including new chemical notices and exemption applications under Section 5.
This creates a direct procurement connection. Pharmaceutical companies and ingredient manufacturers need visibility into whether their suppliers can provide the regulatory information required for US market access.
The current debate does not necessarily concern fees alone. Congressional discussions have examined broader changes to TSCA, creating the possibility that reauthorization could become part of a larger legislative package.
For manufacturers, the practical impact depends on the final legislative structure. A straightforward extension of fee authority could provide continuity, while broader reform could modify elements of chemical review, reporting or implementation.
That uncertainty makes regulatory monitoring particularly important for companies with long pharmaceutical development timelines. Chemical qualification and supplier approval can take considerably longer than a typical procurement cycle.
TSCA Section 5 provides one of the most relevant points for companies introducing new chemical substances. EPA requires applicable manufacturers and importers to submit notices such as Premanufacture Notices before certain new chemicals enter commercial activity.
The current EPA fee structure lists a standard fee of $37,000 for a Premanufacture Notice, with a lower small-business fee. Similar fees apply to other Section 5 submissions such as Significant New Use Notices and Microbial Commercial Activity Notices.
For pharmaceutical ingredient manufacturers, these costs form only one part of the regulatory equation. Review timelines, information requirements and potential restrictions can also affect development schedules and commercialization planning.
A potential TSCA reform process also creates a reason for pharmaceutical chemical buyers to review supplier documentation more closely. Manufacturers need confidence that suppliers can identify relevant chemical substances and provide appropriate regulatory information when required.
This becomes especially important for multinational supply chains. A pharmaceutical ingredient producer may purchase intermediates from several countries before completing manufacturing in the United States, creating multiple points where chemical identity and regulatory status must remain consistent.
Procurement teams should therefore maintain visibility over:
Chemical identity: Ensure suppliers provide consistent chemical names, identifiers and specifications across commercial and regulatory documentation.
US regulatory status: Determine whether relevant substances require TSCA notifications, exemptions or other regulatory review.
Supplier records: Keep regulatory documentation aligned with the materials actually purchased and imported.
Change management: Establish procedures for reviewing regulatory implications when suppliers modify manufacturing processes or material specifications.
These controls can reduce the risk of discovering a regulatory issue after a material has already entered the purchasing cycle.
The financial side of TSCA has become more significant following EPA's recent fee adjustments. EPA's current fee schedule includes charges for Section 4 testing activities, Section 5 new chemical submissions and Section 6 risk evaluations.
For example, the current standard fee for a PMN is $37,000, while certain exemption applications carry a $10,870 fee. These amounts make regulatory planning a meaningful consideration for companies evaluating new chemical substances or alternative materials.
Pharmaceutical ingredient manufacturers may also face indirect costs. Regulatory reviews can affect development schedules, supplier qualification and decisions about whether to introduce an alternative chemical into an established manufacturing process.
The TSCA debate is particularly relevant to chemical importers supplying pharmaceutical manufacturers. Importers need to understand not only the commercial specifications of a substance but also its status under US chemical law.
A supplier outside the United States may manufacture a substance successfully for years without encountering US-specific requirements. Once the material enters the US market, however, the importer and downstream supply chain may need to address applicable TSCA obligations.
This makes regulatory information part of supplier selection. Procurement teams should avoid treating compliance documentation as an administrative task that can wait until the purchase order stage.
Instead, buyers can incorporate regulatory checks during supplier qualification, especially for new intermediates, specialty chemicals and materials sourced from new manufacturing regions.
The September deadline creates a period where chemical companies must prepare for more than one potential policy outcome. Congress could renew fee authority, modify the existing framework or pursue broader changes to TSCA.
Manufacturers should avoid making major sourcing decisions solely on the assumption that one legislative outcome will occur. A more resilient approach involves identifying which materials, suppliers and development projects could become sensitive to changes in EPA review or reporting processes.
For procurement managers, this means maintaining alternative suppliers where technically feasible. It also means understanding which materials would require lengthy requalification if regulatory conditions changed.
The next phase of the TSCA debate deserves a dedicated regulatory watchlist. Companies can focus on a small number of practical indicators rather than attempting to track every legislative development.
Monitor the September 30 deadline. EPA's current fee authority expires at the end of September 2026, making congressional action the immediate policy signal.
Track changes to Section 5 processes. New chemical reviews and associated fees directly affect companies introducing or importing qualifying substances.
Review supplier documentation. Make sure regulatory records match the chemical identities and specifications used in commercial purchases.
Map vulnerable materials. Identify pharmaceutical ingredients and intermediates that depend on substances with complex US regulatory status.
Prepare alternative sourcing routes. Qualification of backup suppliers can take time, so contingency planning should begin before a regulatory change creates urgency.
The TSCA fee-authority deadline creates more than a question about how EPA funds its chemical oversight. Congressional debate over renewal and broader chemicals-law reform could influence the regulatory environment surrounding chemical reviews, reporting and market entry.
For pharmaceutical ingredient manufacturers, importers and procurement teams, the immediate priority should be regulatory visibility. Companies that maintain accurate chemical records, monitor supplier compliance and identify vulnerable materials will be better positioned to respond if Congress changes the framework after September 2026.
The debate also reinforces the value of integrating regulatory intelligence into chemical sourcing decisions. TSCA status, documentation quality and potential review requirements can directly affect the availability and commercial viability of materials used across pharmaceutical supply chains
Featured Product
Found this useful?
Continue Reading
Linde's new long-term ultra-high-purity gas agreement highlights the growing importance of reliable gas supply for highly controlled manufacturing environments. Its capabilities also offer relevant lessons for pharmaceutical procurement teams managing stringent purity and continuity requirements.
South Korea's chemical sector earnings upgrade is reaching specialty materials linked to healthcare and semiconductor markets. Buyers should assess how stronger downstream demand could influence material availability, pricing and sourcing strategies
BASF's litigation against Apple highlights how chemical companies can develop intellectual property that reaches far beyond traditional chemical markets. Through trinamiX, BASF has built patent assets around biometric imaging, material sensing and facial authentication technologies used in consumer electronics.
